Recent proteomic analysis has identified a novel biomarker in ENKTL, S100A9, an immunosuppressive molecule that is overexpressed in serum and tumor samples in ENKTL and likely mediates tumorigenesis by upregulation of PD-L1 expression [115]. This evidence concerns the gene CD274 and neoplasm.